SAB Capital is pleased to present a prime investment opportunity: the fee-simple acquisition of three single-tenant R&D/Lab facilities operated and guaranteed by Velocity Clinical Research. These properties, available individually or as a portfolio, offer stable, long-term cash flow with minimal landlord responsibilities. The offering includes three strategically located facilities: Savannah, GA – 6,880 SF on 0.14 acres Binghamton, NY – 9,984 SF on 1.48 acres Norfolk, NE – 11,008 SF on 2.48 acres Each property is ideally positioned along key regional thoroughfares, ensuring accessibility and high traffic. The Tenant, Velocity Clinical Research, is a global leader in clinical trials, providing innovative solutions for pharmaceutical and biotech companies. With a network of 90+ sites and 220+ investigators across the U.S. and Europe, Velocity is one of the most rapidly growing research organizations in the industry. The company ranked #543 on the 2023 Inc. 5000 list, demonstrating its exceptional growth trajectory. This portfolio represents a rare opportunity to acquire stabilized, net-leased assets in a high-demand industry with strong fundamentals. Investors seeking secure, long-term cash flow with rental growth will find this an exceptional addition to their portfolio.